MetaVia Inc.
MTVA
Last
$1.41
Day
+5.2%
1y
-88.2%
5y
-100.0%
52w
-91.0%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-0526d
EMA 21
1.55
EMA 50
1.60
EMA 200
3.33
20d high
-28.3%
5y high
-100.0%
5y range
0th
Positions held
Your positionsMTVA isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-27
Hold
avoid
Signal
Strong Sell
Target
$1.50
Stop
$1.21
Stop distance
14.2%
Target vs last
+6.4%
Fundamentals
| Market cap | $8.83M | Enterprise value | -$3.63M | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | 1.29 | Beta | 0.96 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -1.8% | ROA | -58.8% | Debt / equity | 0.03 |
| Current ratio | 2.06 | Free cash flow | -$11.09M | Analyst recommendation | none | Mean target | $19.33 |
| 52w high | $14.85 | 52w low | $0.97 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$5.3M | -$3.8M | -$1.9M | -$3.4M | -$4.0M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$5.4M | -$4.0M | -$2.0M | -$3.5M | -$4.3M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$13.0M | -$27.6M | -$12.5M | -$14.0M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$13.7M | -$28.8M | -$15.9M | -$11.4M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-10 · MTVA: Preclinical Findings Support DA-1726 Waist Circumference Reduction
2026-09-09 · MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction
2026-08-12 · MTVA: Dose Titration Complete in Phase 1 Part 3 Study of DA-1726
2026-08-06 · MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Price (daily)
Full chart · RSI · MACD · patternsMTVA · daily-20.2% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin